Research sheds light on how muscle fibres degenerate in Duchenne Muscular Dystrophy
1 Oct 2018, 3:56 p.m.
A novel cell death process known as necroptosis is responsible for the degeneration of muscle cells over time in Duchenne muscular dystrophy (DMD), according to new research from the National Institute for Health Research (NIHR) Great Ormond Street Hospital (GOSH) Biomedical Research Centre. DMD, a serious neuromuscular condition that affects one in 5000 boys, is caused by errors in the dystrophin gene. This life-limiting condition causes muscle cells to be lost over time and scar tissue to build up making movement increasingly difficult.
In this study, researchers based at GOSH and the UCL Great Ormond Street Institute of Child Health (ICH) found that necroptosis, a newly-described mechanism of controlled cell death, plays a major role in the death of muscle fibres in dystrophin-deficient cells studied in the lab.
This research, led by Dr Maximilien Bencze, Research Associate at the Dubowitz Neuromuscular Centre at ICH, found that a protein called RIPK3 was involved in regulating death of muscle cells over time. They also found that less muscle cells die when RIPK3 was absent, pointing to a potential target for DMD therapies in the future. This cell death mechanism may also be involved in other neuromuscular disorders and this will be tested in future research.
The research was published in Nature Communications.
Work using human tissue samples was supported by NIHR via the GOSH BRC
Ancient gene mutation found as the cause of rare hereditary condition for GOSH patient.
UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).
Scientists build whole functioning thymus from human cells
Researchers from two leading national organisations have rebuilt a human thymus using human stem cells and a bioengineered scaffold thanks to support from the NIHR GOSH Biomedical Research Centre (BRC). Their work, which has been published in Nature Commu
Leukaemia trial shows promise and complexity of genome-edited cell therapies
A ‘one size fits all’ immune therapy developed at the UCL Great Ormond Street Institute of Child Health (ICH) could help to clear cancerous cells in children and adults who have exhausted all other treatment options for B-cell acute lymphoblastic leukaemi
GOSH researchers join experts in warning of the detrimental impact of a no deal Brexit on rare diseases
Experts have warned that a ‘no deal’ Brexit will result in the exclusion of the UK from the 24 European Reference Networks (ERNs) that were established to improve the care of patients bearing the lifelong burden of a rare disease, which require highly spe